Real World Outcomes with Idecabtagene Vicleucel ( Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

被引：20

作者：

Sidana, Surbhi ^{[1
]}

Ahmed, Nausheen ^{[2
]}

Akhtar, Othman S. ^{[3
]}

Heim, Michael ^{[4
]}

Brazauskas, Ruta ^{[4
,5
]}

Hansen, Doris K. ^{[6
]}

Ferreri, Christopher ^{[7
]}

Freeman, Ciara Louise L. ^{[8
]}

Afrough, Aimaz ^{[9
]}

Anderson, Larry D., Jr. ^{[10
]}

Dhakal, Binod ^{[11
]}

Dhanda, Devender ^{[12
]}

Gowda, Lohith ^{[13
,14
]}

Hashmi, Hamza ^{[15
]}

Harrison, Melanie ^{[16
]}

Kitali, Amani

Mirza, Sayeef ^{[17
]}

Patel, Jinalben ^{[4
]}

Patwardhan, Pallavi ^{[16
]}

Usmani, Saad Z. ^{[18
]}

Patel, Krina K. ^{[19
]}

Ganguly, Siddhartha ^{[20
,21
]}

Pasquini, Marcelo ^{[4
]}

机构：

[1] Stanford Univ, Stanford, CA USA

[2] Univ Kansas, Canc Ctr, Westwood, KS USA

[3] Moffit Canc Ctr, Tampa, FL USA

[4] Med Coll Wisconsin, CIBMTR R Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI USA

[5] Med Coll Wisconsin, Div Biostat, Inst Hlth & Equ, Milwaukee, WI USA

[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[8] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA

[9] UT SouthWestern Med Ctr, Dallas, TX USA

[10] UT SouthWestern Med Ctr, Myeloma Waldenstroms & Amyloidosis Program, Hematol Malignancies & Cellular Therapy Program, Simmons Comprehens Canc Ctr, Dallas, TX USA

[11] Med Coll Wisconsin, BMT & Cellular Therapy, Div Hematol & Oncol, Dept Med, Milwaukee, WI USA

[12] Bristol Myers Squibb, Princeton, NJ USA

[13] Yale Canc Ctr, New Haven, CT USA

[14] Yale Sch Med, New Haven, CT USA

[15] Med Univ South Carolina, Charleston, SC USA

[16] Bristol Myers Squibb, Princeton, NJ USA

[17] Yale Sch Med, New Haven, CT USA

[18] Mem Sloan Kettering Canc Ctr, Adult Bone Marrow Transplant Serv, Dept Med, New York, NY USA

[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[20] Houston Methodist Hosp, Houston, TX USA

[21] Neal Canc Ctr, Houston, TX USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-181762

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[31] Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: real-world experience from the US myeloma CAR T consortium
Afrough, Aimaz
Hashmi, Hamza
Hansen, Doris
Sidana, Surbhi
Ahn, Chul
Dima, Danai
Freeman, Ciara
Puglianini, Omar Castaneda
Kocoglu, M. Hakan
Atrash, Shebli
Voorhees, Peter
Shune, Leyla
Simmons, Gary
Sborov, Douglas
Ferreri, Christopher
Wagner, Charlotte
Patel, Krina
Khouri, Jack
Anderson, Larry
Lin, Yi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S33 - S33
[32] The BCMA CAR T cell therapy idecabtagene vicleucel (ide-cel/bb2121) in relapsed and refractory multiple myeloma (RRMM): outcomes from phase 1 study support the phase 3 KarMMa-3 study design to compare ide-cel versus standard triplet regimens
Einsele, H.
Raab, M.
Kroeger, N.
Fenk, R.
Scheid, C.
Munshi, N.
Petrocca, F.
Hege, K.
Novick, S.
Raje, N.
Kochenderfer, J. N.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 140 - 141
[33] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A CAR T THERAPY TARGETING BCMA, IN PATIENTS WITH MULTIPLE RECLAIMER/REFRACTORY MYELOMA (MMRR): UPDATE FROM THE KarMMa STUDY
Albert, Oriol
Jesus, San-Miguel
Ankit, Kansagra
Deepu, Madduri
Nina, Shah
Philippe, Moreau
Ibrahim, Yakoub-Agha
Michel, Delforge
Michele, Cavo
Hermann, Einsele
Hartmut, Goldschmidt
Katja, Weisel
Alessandro, Rambaldi
Donna, Reece
Paula, Rodriguez-Otero
Fabio, Petrocca
Jamie, Connarn N.
Payal, Patel
Huang Liping
Timothy, Campbell B.
Kristen, Hege
Nikhil, Munshi C.
HAEMATOLOGICA, 2021, 106 (10) : 76 - 77
[34] Cardiovascular Adverse Events After Anti-BCMA CAR-T (Ide-Cel and Cilta-Cel) for Relapsed/ Refractory Multiple Myeloma
Palfi, Stefanie
Koelmeyer, Himara
Alsina, Melissa
Baz, Rachid
Blue, Brandon
Corallo, Salvatore
De Avila, Gabriel
Freeman, Ciara
Grajales-Cruz, Ariel
Harvey, Kristy
Liu, Hien
Nishihori, Taiga
Oliveira, Guilherme
Oswald, Laura
Puglianini, Omar Castaneda
Shain, Kenneth
Wettenstein, Zachary
Jain, Michael
Locke, Frederick
Alomar, Mohammed
Hansen, Doris
Lee, Dae Hyun
CIRCULATION, 2024, 150
[35] Subsequent Anti-Myeloma Therapy after Idecabtagene Vicleucel (ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma from the KarMMa Study
Rodriguez-Otero, Paula
San-Miguel, Jesus F.
Anderson, Larry D., Jr.
Lonial, Sagar
Truppel-Hartmann, Anna
Sanford, Jill
Rowe, Everton
Campbell, Timothy B.
Munshi, Nikhil C.
BLOOD, 2021, 138
[36] French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry
Ferment, Benoit
Lambert, Jerome
Caillot, Denis
Lafon, Ingrid
Karlin, Lionel
Lazareth, Anne
Touzeau, Cyrille
Leleu, Xavier
Moya, Niels
Harel, Stephanie
Perrot, Aurore
Bories, Pierre
Vincent, Laure
Lamure, Sylvain
Mohty, Mohamad
Malard, Florent
Manier, Salomon
Yakoub-Agha, Ibrahim
Stoppa, Anne-Marie
Brisou, Gabriel
Decaux, Olivier
Houot, Roch
Le Gouill, Steven
Facon, Thierry
Avet-Loiseau, Herve
Moreau, Philippe
Arnulf, Bertrand
BLOOD, 2022, 140 : 4668 - 4670
[37] Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma patients treated with idecabtagene vicleucel (ide-cel)
Rytlewski, Julie
Fuller, Jaymes
Mertz, David
Freeman, Ciara
Manier, Salomon
Shah, Nina
Campbell, Timothy
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S46 - S46
[38] Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study
Lin, Yi
Raje, Noopur S.
Berdeja, Jesus G.
Siegel, David S.
Jagannath, Sundar
Madduri, Deepu
Liedtke, Michaela
Rosenblatt, Jacalyn
Maus, Marcela V.
Massaro, Monica
Petrocca, Fabio
Caia, Andrea
Yang, Zhihong
Campbell, Timothy B.
Hege, Kristen
Munshi, Nikhil C.
Kochenderfer, James N.
BLOOD, 2020, 136
[39] Idecabtagene vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study
Goldschmidt, Hartmut
Raje, Noopur
Siegel, David
Jagannath, Sundar
Lonial, Sagar
Munshi, Nikhil
Moreau, Philippe
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Huang, Liping
Agarwal, Amit
Wang, Julie
Campbell, Timothy
San-Miguel, Jesus
Reece, Donna
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 50 - 50
[40] Quality of life in patients (pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with the BCMA-DIRECTED CAR T cell therapy Idecabtagene Vicleucel (IDE-CEL, bb2121): Results from the KarMMa trial
Weisel, K.
Einsele, H.
Goldschmidt, H.
Delforge, M.
San Miguel, J.
Bertin, K. B.
Tahir, M.
Lewis, H.
Wang, J.
Braverman, J.
Campbell, T. B.
Munshi, N.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 93 - 94

← 1 2 3 4 5 →